| 000 | 01794cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030444.0 | ||
| 008 | 110905s2011 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.18.M.Sc.2011.Ah.S | ||
| 100 | 0 | _aAhmed Farag Ahmed | |
| 245 | 1 | 0 |
_aSolube receptor for advanced glycation end products in patients with renal impairment and hemodialysis patients / _cAhmed Farag Ahmed ; Supervised Hanan Abdelhalim Abdelrahim , Mona Mohamed Roshdy , Layila Rashed |
| 246 | 1 | 5 | _aالمستقبلات الذاتية لنواتج التسكير النهائية المتقدمة فى مرضى قصور وظائف الكلى ومرضى الغسيل الكلوى |
| 260 |
_aCairo : _bAhmed Farag Ahmed , _c2011 |
||
| 300 |
_a114 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine | ||
| 520 | _aSolube RAGE is a naturally occurring inhibitor of pathological effects mediated via RAGE . Protective sRAGE levels are decreased in patients with coronary artery disease as well as in patients with hypertension . Patients with decrease renal function arre at high cardiovascular risk and often have hypertension or diabetes factors that decrease renal function | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aGlycation end products | |
| 653 | 4 | _aHemodialysis patients | |
| 653 | 4 | _aRenal impairment | |
| 700 | 0 |
_aHanan Abdelhalim Abdelrahim , _eSupervisor |
|
| 700 | 0 |
_aLayila Rashed , _eSupervisor |
|
| 700 | 0 |
_aMona Mohamed Roshdy , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c35047 _d35047 |
||